PODD - Earnings call transcript Q3 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Third Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time.

As a reminder, this conference call is being recorded. I would like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations and Corporate Communications.

Deborah R. Gordon

Kevin. you, Thank thank quarter and joining for us Good earnings you call. third XXXX our afternoon for

Joining are and our on in full-year discussing guidance also Officer; Shacey Officer. Petrovic, Senior press available our me Executive President website. The President fourth Chief third today Vice will be call our and Patrick and replay Sullivan, of Chief Chief Operating and and and archived this quarter Levitz, and Michael IR quarter of Financial Chairman section the our website, release XXXX results Officer; is

results that, turn we implied our inform during statement, Harbor such statements the materially company's different Before the by our factors actual filings release, begin, in statements. over call involve that I in of and course in unknown referenced to would include and may Insulet I'll cause any you with uncertainties from by and the to forward-looking With future may call those and to like Safe known results Pat. made be this third earnings be certain quarter the Such risks that SEC.

Patrick J. Sullivan

review today. Thank for joining call key three thank you, and with performance I'll the third our you begin making Good a the in Deb. on our quarter us afternoon, brief and of we're everyone, progress initiatives.

our number Specifically, I'd and to on number Month. Diabetes we'll up our establishing is results one, November operations. provide transitioning full-year manufacturing comments to then two, first next-generation commercial platform; third progress, recognize distribution completing XXXX, Dash, R&D direct Awareness Europe; guidance Shacey our like and that questions. will on on technology on call financial our open for more product the provide three, for U.S. and development Mike QX Omnipod National then quarter in and our detail will

patients. of life elegant to managing with We that reduces we Omnipod every for burden and simple proud delivers the technology improves life, better quality simplify are of of what outcomes provides day do and The for the disease, people very diabetes. health

part at Next Closing increase will ceremony the diabetes Monday, take Bell we to in NASDAQ awareness.

the revenue million year-over-year. outstanding performance. For year-over-year guidance was up XX% third business quarter, Total and growth a quarter year-over-year, our revenue revenue the the XX% and Delivery Drug $XXX $XX of range. revenue XX% of was midpoint million, of million, International was $X area million, third million, for Omnipod above U.S. up $XX $XX.X XX% year-over-year, our up was delivered every

remain of our drive XXXX. was towards improvement XXX and year, XX.X%, we confident gross last our Our an completely ability of in QX XX% margin points to in basis from margin gross

a As from outlook million, XX% a year-over-year for growth. performance million of $XXX full-year of of revenue this guidance expected $XXX our we're guidance, range the million positive better our to our midpoint of and year, raising remainder a than the to increase previous result $XX and

Horizon Automated During our we made future System. Omnipod Lilly programs you more and the Dash provide commentary Glucose concentrated Dash development quarter, will our Control the insulin with of Dash. the the is platform innovations, of on technology system. for all including significant Eli progress on Shacey our

per products the has the We customer, the to doubled focused ops which time. on with has meet at pod continue our chain, to as our years, the high, scrap, our delivered Over every a product pod daily improvements supply base day. an impacting production manufacturing installed gross every team continue drive the closely is reduction all just three ensuring quality highest past in greater now than grow. positively Since we margin quality. our customers' providing contract needs manufacturer, to the XX% to is our time, And outstanding continues and on are and XXXX, and team, all-time sustained the operations production working

We over facility held with This Massachusetts We redundancy current weeks all attendees, a are establish increased second mitigation capacity, ceremony Governor, ago including groundbreaking on chain will state-of-the-art strategy. to our provide importantly, several Massachusetts. risk speaker. the new our XXX new keynote in source and part our facility contract Charlie to manufacturing supply schedule manufacturer, Baker, as of

building facility a We are new that world-class will the a set in industry. manufacturing standard

transition be system beginning to rather highly over than is X, automated will in made, middle and revenue pleased first in of the through the and and in markets. transition next XXXX. steam July our of year. recently pipeline Selling us and about input decision excited our existing and distributor to in a be our our customer line This significant have our the Omnipod for closer early market gross to improvement service we've and direct European international control full result ahead by We're The maintain to to to opportunity announced transition progress ability in successfully scheduled Europe product with We're placed in establishing We remain XXXX. business this our distribution operations. direct a allows the in confident margins. development the future we

on We billion to of achieve way XXXX our in targets revenue, above XX%, profitability. gross approaching $X our are market and margin well

and excited shareholders. trajectory, We for strong shareholder creating our to to remain the turn our growth over our Mike. the on are opportunities I'll for pleased are that, with we Mike? accomplishments call value focused to With – date, continue

Michael L. Levitz

I discuss XXXX quarter Thank guidance. and then you, third our results and will Pat. quarter full-year our fourth review

all As be stated, I commentary unless basis. will otherwise a review regarding changes on year-over-year our results,

on this million, Omnipod, of our across continued million, with also strong Omnipod, growth the our $XX.X with lines revenue exceeded of majority We are $XXX.X in was such coming contributed three product beat quarter by the the The momentum. $X meaningfully third on midpoint France. in strong the European as remainder quarter the from International including growth. beat markets, continued report newer guidance stated our very momentum pleased led third of U.S. markets of to strong of We to to by million. All the growth revenue compared XX%, of

gross supply well and to product Our higher chain to over primarily part last from improvements in XXX as to points sales. basis the made to unfavorable distributor international due increased our quality, by improvements mix operations, margin manufacturing over XX.X%, year offset we've as

We first which for time above at are XX% result very to a the in the quality both Insulet, pleased execution driving direct is efficiency. reach tremendous of team's and

in in year $XXX over $XXX includes our This last million, previously ended We from head is growth to million operation direct of plans. capital end our of the support decrease spending is increased Our over operating product as with associated in approximately for compared U.S. our to $XX.X and investments cash significant in to investments we've expenditures, $XX.X quarter the in compared our in also investment investment supply year investment, the added a our increase the assumption project of primarily business, other count to Europe, support expenses our supply increased The and and business. result This with support commercial million. growth contract increase reflects stated last global the to and such Omnipod last operational at mid-XXXX infrastructure. of our consistent in to innovation commercial and with manufacturing million in and that year. manufacturing chain

our sales strong growth as also business. investments well inventory reflect even with stable as outstanding, levels days continued Our and of cash the

strategic longer-term a We financial our continue to position, you and of growth update support near investments now XXXX opportunities. make as we organic I on outlook. in strong are our in will

the on be with and revenue growth $XXX midpoint at outlook and continued XX% For U.S. better exceptional are to demand markets the line associated of previous business, largely market. at both compares the raise the is midpoint. of the raising full The our represents to midpoint. now the strong revenue in high-end up we representing range date of given a year, XX% $XX and of and $XXX of at Omnipod to to XXXX our of $XXX full demand the The revenue million range from $XXX guidance Omnipod range to U.S. in million in $XXX growth in expected than strong At $XXX million, level, we million, momentum million. million, million low across the product to $XXX revenue expect year revised million our international the

$XXX range We at to in Delivery of representing line our with we expect stated Omnipod expect the and in growth $XX.X $XXX million XX% midpoint. Drug million, of previously representing range growth And International revenue to million, the be XX%. of approximately

XXXX, representing growth of expect the growth we to $XXX.X of fourth revenue XX% XX% $XX.X the For $XXX quarter line a fourth revenue in midpoint. at of $XXX we representing quarter and midpoint. product of million range $XX.X at million U.S. At compared to the the Omnipod range million, the million million level, of and expect to in

we represents our range This approximately previously on reaffirming made, gross be reported XX%, year. of million the at representing QX, in continue X% Delivery to Drug expect XX% of be timing Delivery full-year of expect to a midpoint, decline Omnipod the a some Drug expect We $XX however, This million. basis, million, again, and International between to QX and XXXX, the our faster to partially last gross reflects due are to our line full-year up expectation in we've we revenue. revenue growth $XX mix by unfavorable international XX.X% compared we growing with to On from improvements substantial guidance. stated operational distributor significantly the to margin margin, approach offset will $XX.X

in made reaching expansion, revenue pleased investment. and gross We we To margin we of development, confident our longer-term achieve are the and our in we commercial, invest margin. and of have continue profitability goals, our will progress and research with to infrastructure very including business, goal approaching XX% are tremendous growth

We operating from previous spending which our with is XX% initial European line XXXX, expand expenses our in and and between infrastructure, expect to XX% full-year guidance. includes to XXXX increase

expansion revenue our profitability. our represent operations Pat to opportunity European both plans track, Omnipod responsibility commercial on As mentioned, drive assume over of are a continued and direct tremendous to and

run user European higher on lower Europe drive distributor XX% continue a in by of to direct average revenue the XXXX, pricing, is than rate while is the increase approximately than in a pricing. which We our transition historic the material expect driven U.S., our business half end in in will second pricing to

also company calendar the half to expect basis, year margin by XXXX, for gross of We assuming expected total a basis increase full-year this that with transition. in an XXX midyear drive points on approximately

innovation Shacey. goals exciting of the year next to years I over and our our deliver improvements, stated to the strategy, on line business, sustainably operational EBIT profitability we will coming our turn with to the strength and beginning above-market objectives. call positive track Lastly, driving in and on remain continued over growing now

Shacey Petrovic

Mike. Thanks,

were heading into Third terrific, again quarter. quarter once strong fourth the results with momentum

And increase with our as made and Pat share strategies we've continue expansion manufacturing in is The moment. more drive growth robust efficiencies, strategies commercial and across-the-board that of to progress revenue in to product continue our innovation our and Our our operational I'll noted, an drive in installed margins. pipeline improvements and base. about global a exciting, quality,

U.S. the exceeding installed XX%, revenue than grew Combined, revenue third reminder, expected, year-over-year the of our customer because base of our In And we growth. third-party year-over-year which of is more represents predictor international our because recurring base goes our is an company the growth half XX% of and strong as as installed best approximately drove end majority approximately our installed a As XX% in the QX, installed Omnipod's of base model, this and customer our estimate revenue base our we through base U.S. distributors. of of global expectations. growth. quarter, growth international base installed about grew base

As installed year-over-year a base up our we're anticipate approximately full tremendous internationally, growing result experiencing year, of for now worldwide from prior the XX% expectation XX%. the we of our growth

are of of raising expected our of XX% reaffirming growth approaching growth and the from base our are to we U.S. prior installed assumption in XX% international We estimate our installed XX%. base,

raise revenue continue continues marketing the broaden field footprint fueled and These to they drive are U.S. be our clearly by team, paying to our be sales awareness, to off. market to areas Our invest which access. in increasing of growth efforts we will because

have our U.S. estimated the expanding growing of was who management data are well average, demonstrate designed make clinicians, our to and do utilization almost provide AXc Dash for better XX,XXX installed and and Omnipod. of the supporting clinical The patients, the most is among over and pod body system our This the Omnipod's while you an conference, Bluetooth connectivity unique than with are liberates access. data sleek, the meaningful cost to our Omnipod AXc using could advocacy low to in is provide the Bolstering in used of continue Insulet of mobile data improving use At particularly upfront through incredibly who our notable half X.X%. from particularly This Provided customers, and change takeaway most of strong of Dash of measure. The customers the insight Association technology, Insulet patients users with PDM the Podders innovation XX,XXX an the enables sets real-world efforts also Dash is to benefits. product awareness, At is connectivity. to now real-world of than large Dash advantages, be Glooko. payers, Omnipod our to end brand of user data evidence unparalleled we compact, because value notable This visible Provided the what touchscreen clear, as PDM. We users. Omnipod national base, more many change helpful system. payers can't see, an Omnipod Medicaid for all Study Diabetes performance population, for benefits ease our increasing shared we we recent on same physicians, We European with progress and roadmap, rich, important with include Omnipod U.S. Glooko. time, the

data this to payer, aggregate the diabetes through populations their on Dashboards. access their specific membership and Omnipod outcomes For means

their data clinician, for access office Omnipod health ability their and phone, therapy on immediate View the information means delivery our to workflow fingertips, the app and with an at Their less data with Dash or For therapy training pump to streamlined on access this right patients, their for interactions their their share data they patients where diabetes insulin their fitness diabetes improved the And mobile means patients. and CGM app. control their data on via PDMs data. time this will to easy or caregivers phones PDM their their pod be mobile their and on view

feedback, our way to they our we pleased love confident on this have and report will platform, customers very successfully will that we (XX:XX) Dash, the are which based factor We early their for completed human transform summative manage studies product diabetes. new are

We submit and Glucose for a XXX(k) marks around mid are is This next track since our System. platform Horizon very year market for our of innovations, Dash to the concentrated to and launch future milestone limited the the on this end Control our year. Insulet, anticipate FDA Automated insulins product a including important

now adults our to monitored Horizon make We continue Omnipod on patients algorithm. XXX great including progress Horizon with and pediatrics, We development our adolescents, program. have

age normal are the the hybrid longer We to with which currently algorithm third across in continue during performs results living our setting underway day our IDE, all time is well, phase. our demonstrate conditions, with study hotel spending very Horizon safe a is taking The and and place in patients under night groups. a that closed-loop

business, we expanding progress Turning made infrastructure. European International our to have substantial our

business on strong We foundation our are of Omnipod year. next of a successful building July for a transition X

bench longer deliver as on international quarter, we past quality, affairs. regulatory expansion and near the in strength and over hiring talent term. ensure expertise focused we are This Europe such market the have key IT, rapidly functions high to We and caliber commercial, to

a and about we year growth, business We to ago just model installed business with every of growth launched it international significant the base our markets clinician a year are Canada, to to in full will be Europe. to ago, In one installed of assume including all our us the base, total of control in about direct installed care France, This our and near us or control Kingdom, change deliver Germany, our Omnipod allows a international distributor contributor the user In for Remarkably, remains ready rapid outstanding a because our supports better quickly growth. base. to and in the continuity market our France on exciting in contributing term, can third meantime, Insulet, experiencing largest Europe, pricing base. expansion and for we average value for the United European and representing market the accretive. term, pricing see is customer our the we drive and needs. innovation the which it give our needs growing we global entries. to imperative, a ensure This move shareholders, and importantly, opportunity and those we accelerate expands International and strategic best margins this based as and for is to longer international business, that customer means meets an in insights difference it our will between And new deliver that just

supported And of Drug market's Neulasta of third doses remain remain We of the reached about of business continued our which at adoption prospects by pharmaceutical Delivery strong Amgen's our about non-insulin of for the working of the remain U.S. quarter. XX% excited more Onpro the and can Amgen. therapies comfort that the our Neulasta with all benefit results convenience other our kit, generally, end we Lastly, partners pod. of excited from partnership with delivery

attractive We a has what represents continue period Delivery long-term I of our for short proud to In growth. incredibly in believe relatively am time. closing, of accomplished Drug team opportunity an

improved We strong and a long-term performance that, turn board I'll and have growth With driven to foundation established Pat. across for the call success. the back

Patrick J. Sullivan

Shacey, let's much. up now, the for Operator, questions. open you thank call very

Operator

Thank you.

Morgan comes Stanley. question Lewis first Our David from with

David Ryan Lewis

program exogenous XXXX big should one Good two, I quick these investors quarter. know being of follow-up. as team, qualitatively markets expect numbers, a just those because and into Can it's customer growth next thought congratulations we announced, and Then about year, but we impact Animas acceleration only Could early, in on of expect the I could two qualitatively those events? that that could maybe XXXX? afternoon in this little you've think, Pat kind could there got I things a what terms growth year great talk about another I given next very your similar for rates? sustained are year's mean, go direct you these talk ex-U.S. two mean dynamics as relative I dynamics. well

Shacey Petrovic

David, maybe question that in addressing program in regarding place been fact, working in the with can get have two we've to not of the Dexcom, our get it's to educate help Omnipod, just We there transition options to and been start I'll segment. by and it's things But Animas. out and mind, they word keep out. users Sure. Animas have fun a kind do target to that is

very coming going of are even quarter just our XX% year. because track any is I'll mentioned well. that give our that model, this to because quarter, And to more I on next really thing with segment. I just think of of change dramatically going to quarter substantive XXXX. And kind from we're of like that's kind we or or still don't target guided might one beyond. other recurring So end comment make anticipate I or to a for have customers don't the on is I obviously like any that wouldn't every revenue the be MDI. new it's reminder over we're in given is And but not a the quarter, think because that going Ypsomed, impact anticipate transition just other time as to that that, that you particular feel guidance the ready of everything we for year, opposed

Michael L. Levitz

on expect last in the I add is a of the I would is strategy quarter, material only consolidated for just going business as The and run go-direct our rate said to we Mike, change said business that, that do and is to thing model. we the impact because this as have

historic second the though pricing a than XX% even direct our year, our the we of lower European in distributor so, we expect of based U.S. because is is approximately because upon pricing, user appreciation middle pricing the the do – rate the that. end in from go – the with half significant And run a will in XXXX, when be uplift on pricing historic our average, is XX% revenue

in here. increase even all been talked years describing And will we've revenue about basis, a corresponding business result increase a that significant margin, will a and the from volume beyond increase model midyear a points basis XXX of over gross last impact that points. so XXX in so And increase the impact a on the we basis the in be few growth full-year of change assuming significant

effectively. but For be both hopefully, we've model a we would drive business of given to change the model, in those, able enough you expect to that

David Ryan Lewis

And here. just helpful, very It's follow-up then Shacey, quick my Mike.

quarter, the much the strong, obviously about number but thinking was ex-U.S. better Just was than U.S. expected.

the how are back Just a expectations, in the mean, little year, France, give traction what is and of the of with perhaps is half expected of into sense to of this disruption much. of less the markets than early of this relative your France? how Thanks us this much changed much I or sustainability here part the so transition much other that is how transition, you potentially to the or unrelated

Shacey Petrovic

Yeah.

say, I first has it's Really, you been mentioned. would think two transition that I going those the smoothly.

less than we have in still anticipated. France. And And we so across the we disruption have particular, in growth and continent, strong continued

the of for those in are rest So the year. the of uptick both of things kind the driving guidance

Michael L. Levitz

quarter, growth this that to because did I'll momentum that giving We that our realistic since last last Mike gave that is to just of guidance before, built had as was risk, a that after and going related is realistic conservatism the result, shortly going continued was reflects And be in felt on we're just it we to direct, into been we call, unknowns We We've transition. the and is our some business. were the announced just potentially and this number that. conservative. add the there we of less retiring now guidance was that indicate, again, really

Operator

Jeff from comes with question next Baird. Johnson Our

Jeffrey D. Johnson

it's have of you probably I with just following period, on running question been Animas, before want they're One, unlikely or Good move out guess but me you've afternoon on I otherwise of as they'd to afternoon. up pocket. users David's out know that conversion confirm for Animas maybe Shacey start the Thanks taking warranty to program, Mike, I paying two for this questions. well.

upwards from with to in extreme popular my the We're I we're they being also – here Animas about option on pediatric just talked patients. numbers? X,XXX night, X,XXX at had a over a Animas, think that And would lot guess to pump pediatric in an with XX,XXX I to but come near of why pump. year going term, right patients couple is, XX,XXX see all Does match I all hearing or Dexcom of those on it expect Animas period the pediatric last Omnipod? Animas maybe not So a to U.S. your not patients over

Shacey Petrovic

your numbers similar are segment. I Omnipod, but those not to ours, in to the would would ballpark reiterate think come Jeff. some target expect our over I And to just I we of think it's customers

a already So, in wearing from vast any customers year, tube probably to their of in And options. don't tube I create transition majority the customers given our big users. they're or that's happen of as we is a all going or pump, given to to agree year. of opposed they're MDI a something pumps bolus next at over that going quarter from Most if would years, look two come coming a a even this that's given to get the our going comfortable quarter

Jeffrey D. Johnson

the as Thanks. market I've after seeing FDA my another supportive And devices this pretty for as of diabetes market possible. I something being quickly before, them seems like we you right. to example the just more new win of don't or data, more giving maybe I have it to getting broad and uninspiring the know, for Libre Abbott then All think with somewhat, but asked like follow-up, approval guys

get about we you able predicate? context, that might especially the XXXX, had conversations if the have market X.XX market to you in some (XX:XX) or be in guys which a before any Horizon point on that as pathways FDA have to accelerate with So the

Shacey Petrovic

We've certainly well. been the us our I pre-submission But to efficient as type ready submission Dash support Horizon, multiple than and effective we're a We we a with as to say had product pathway for they of And to us so the and and very that, as of how have can't get that color. the discussions I had as in with have give tied quickly of possible. lot helping we've regular discussions supportive terms clinical and FDA in development enthusiasm can. Other FDA. discussing same always as market getting would make

Jeffrey D. Johnson

Thank you.

Operator

question from next Matt comes Taylor with Barclays. Our

Matthew Taylor

taking a for the on good congrats thanks quarter. and Hi, question,

wondering the could So first that's was, now, X lower a address, your business of I think one and about think was from a on competitors at I a or And at if that market year talked a type cost you to all? talked ask for maybe one launching question also patients? directly you developing patch ones wanted about to future it's your you you encroach could not whether pump

Shacey Petrovic

really I Matt. market. market, Sure, X to is concentrated because would frequently on type designed about with actually Lilly the address say, insulins pretty talk partnership we our Eli that

they require. type the volume of One that of X people the differences versus X between the customer needs with insulin who live type with is

so, UXXX factor pod. concentrate we've pod form the that approved have, the great we form with and partnered insulin Eli factor UXXX and to their the out and get the to keep in order And small of Lilly

that other manufacture manufacturing really And programs in at very do, shown on platform that's track, we've and to UXXX really the serve high progress, and pump So such the nicely. think got patch out we've underway that that will out terrific on and product about what's and think you is able I that those can be in just program appealing. is clearly anywhere excel. of or – so really think us an well how I made elements segment of UXXX pod, this some we've a will customer to be point I is customer the or But where launching the a operations market. then the United the do about important rate that also made the competitive we of high and advancements help States well those product that, area where that would approved differentiator, very excellence are I rather operational differentiator, globe We've that quality, we that's the and because progress and address volume

Matthew Taylor

the quarters, look how secondly, you've this and to Ypsomed side to to sounds That's or international lot you great kind as point execute smoothly aside well really transition, brackets would it that of for some investors able us for as perspective. then next are on you'd that be the understand protection, forced couple well through but And put going? in place that's the international like a contractually of maybe from what growth, to to over guideposts good

Shacey Petrovic

speaks work grow quarter, while by XX% warmly been we think really great probably transition community clinical the with for installed making growth rapidly We're base I to Europe. the We've The progress. year. welcomed Ypsomed really next continues in this Well, to itself. business

I at in last, events presence Austria market. only UK, diabetes EASD support we in us direct symposiums and at the really, expressed and two their sincere (XX:XX) Over and enthusiasm with have so clinicians and our in all held in the have workshops and Portugal, Europe, over room EASD really – their months the guess, about children been a establishing product standing

that be So thrilled happen. to making we're

base indicator I is of doing we're installed at how really growth. looking the best think the

Matthew Taylor

Great. Thank you.

Operator

comes next question from Our JPMorgan. Mike Weinstein with

Michael Weinstein

another on quarter. congratulations and Thanks strong

a ask couple just me Let questions.

market your France, you on now? is do think Just share what

Shacey Petrovic

a looking kind United my around guess. type we don't against into there I generally XX%, be share have pumps, from even diabetes Europe than market would we're said before, it total XX% insight Mike, the do X we at of other and guess, less somewhere we would opportunity standpoint. track into we States, so,

Michael Weinstein

Okay.

Michael Weinstein

has business, by think that they're couple you've And about of installed since your when that comment I are said J&J I've XX,XXX generally XXXX. patients basically exiting XX% of to base XX% your U.S. numbers the of patients last MDI, end from XX% years. announced close that shrunk to imply they the their got We heard again

fair it You those and of amount a don't somewhere, gotten seem business benefited from patients doesn't it. think Medtronic's you've that like necessarily patients, those went would look it

patients I'm of maybe years. has patients base and two are than installed year a kind that more as much think? gone, and last declined just not those over their the of you So, those it getting Where wondering half, as has you had

Shacey Petrovic

– come come we is it's that taker. of just That's what target in pumps. and that from clearly the is XX% the we that so a our grower, and the think segment I majority our those in ourselves approach. MDI, I included not probably that our Well, from patients XX% and is I'm patients or are in there's saying our what our really, not a not numbers consider we evident strategy, strategy the share think category vast

Patrick J. Sullivan

I just add, And would Mike...

Michael Weinstein

where But you that get do that number, XX% Okay. from?

Shacey Petrovic

We they're patient and get track categorize track we and from. every on, comes a where so that that, coming prescription new

Patrick J. Sullivan

from don't they're pump pumps, is on XX% have don't Pat, coming And we this coming we which are the that – from. visibility

Shacey Petrovic

just That's they're pump MDI. right. from We coming therapy whether know or

Michael Weinstein

you. Got

you. Thank Okay.

Shacey Petrovic

Sure.

Operator

Our Matt Jaffrey. next comes question from O'Brien Piper with

Unknown Speaker

place wanted some Hi. some make had or sort ask it Good go they July, maybe did This end in through want – incentives had through for internationally afternoon. some there? some is forward to bogey of July. your I clarification Did sure the on wasn't Matt. you international go taking on Thanks I (XX:XX) this of they for the it to there year? when remainder negotiated that to I pulled sales, hit question. you for the JP was strength, – know just that agreement the of through

Shacey Petrovic

don't of base, want track We all, right. installed we – No. their first

what reported and that's was on, So that very I strong. obviously out

roughly there needed with independent wasn't of to they they line, this particular even that I this achieve revenue anything their quarter. So transition think but and were in no,

Patrick J. Sullivan

to both Yeah. there modifications of anything. XX agreement, Because parties through no and it their contract by goes next that bound contractually June year, or so were

Shacey Petrovic

is actually tied of XX that to termination so... happened sales agreement, after incentive the months the And the the

Unknown Speaker

here Can incurring you of good Okay. our in ramp, this up we'll help us out and know. half can I look walk you're out costs And things, a maybe get side revenue models, some cost quarter second break and next already run to started know and we year. margins for internationally. quarter QX of starting some (XX:XX) year? costs we in as next through the the of It's all incurring And gross you bump then good QX, on next to so on rate

Michael L. Levitz

Mike. Absolutely. This is

this we operating things, the it about in a of raised also raised last things really some get call for in said our the we off by we a the was year. go, to this spend time, planning and for contingency ramped we growth, run So, and operating though of even XXXX, quite expense and indicated reflect where to year would X we expectations as rate this quarter points this that we ground the really been up we've couple expense saw

So, million $XX about or X take. is roughly points off of last year's OpEx give

full last what for talked $XX what for we middle indicate that the million up fair would operating rate of will XXXX. a next think said ramping running into half be way said to The of that million And what get to is, that's year. – going we and that's I are about of the we now, XXXX So in expense first ramping it's quarter more up year. from we we run is, up work $XX in we when the

half get having so, once And and margin comes the the we expenses before in of more the of go that we'll we second be direct pricing the year.

Unknown Speaker

there on then any And Medicare? update is

Patrick J. Sullivan

to Pat. confident a is that This Medicare of just From secure remain my very going time. Sure. reimbursement. we're it's perspective, matter We

an the complete members time. we're can't and medical of have very give confident Medicare the you I of Congress, to And reimbursement. just going that exact We many professional we remain support get societies.

Unknown Speaker

Got it. you. Thank

Operator

question next with Margaret comes Our from Blair. Kaczor William

Margaret M. Kaczor

Thanks guys. Good question. taking afternoon, the for

you've general on The of if many penetration seen that the guys you've is market in in France change patients of first those I'm And for me sense curious of comps And any you since coming how of one are France. from entered. rate that MDI? you have seen and

Shacey Petrovic

because you today. bit or of markets, We're of meet strategic mean, closer probably as we closer feel of that That's year, sometime I is But it's Margaret. this I the got research preparation France. don't a of for level insight ton but this we for like we we cetera, looking in as will one you're et to that transition. I reasons with insight the you're imperative question, exactly all can't underway in why asking that next have clinicians, and this, little a to our about to great give a market get international we've Unfortunately, get it gaining a

Margaret M. Kaczor

assume you're of do comps, the... guys given accelerating would adoption that I think that But you the

Shacey Petrovic

Yes.

Margaret M. Kaczor

had you've internationally. success ...

Shacey Petrovic

Yes.

Patrick J. Sullivan

is is the rate it in it is Europe the also rates penetration is general, attrition are – in than lower The States. than In United the United lower States.

it's... So

Shacey Petrovic

heard there's to And injections clinicians daily from coming we in from know specific I a that France. multiple pod the don't have just large number numbers. the of patients

Margaret M. Kaczor

wasn't of then be to maybe there adds, P&L? you any as contributor question, going focus in that on a Animas a you any Thanks. chance the know just as going is big be from terms typical adds that maybe Animas bit follow-up patient a patient little but that's the I on going And there of population, is quarter, to Yeah. to and to as impact each distract

Shacey Petrovic

There activity internally. actually will not is be distraction. handled Most this of

multiple on program target went most through both call team, really channels Dexcom segment, of is the daily opposed users. which us. and volume, our focused but by who is as the team So out our work field to digital that has the And remain increased that from handled injection internal

to impact P&L, think Mike, either. that. impact In to you don't confirm the should P&L terms the of any there's I

Michael L. Levitz

as a... just said we it's Really, from what Yeah.

Shacey Petrovic

Yeah.

Michael L. Levitz

to and think there a ...guidance grower, this nice MDI of perspective. our traditional business, we number opportunity. is a grow only is this are not And opportunities but

all a positive. it's So net

Shacey Petrovic

a cost the pathway system, cost And onto of the no can model, recurring revenue because get low beauty the of or cost. we low upfront people a because

Operator

question with Doug Cowen. next comes from Schenkel Our

Ryan Blicker

use is this on their of Doug. my Ryan with of continue the sensor on talked Dexcom, that it call in calibrated as taking starting should Maybe Horizon or to launch, about first by a Is of yesterday, to the able we one GX to XXXX. having their once-per-day the for would Horizon. part getting on about a there questions. version clear that for your end market think chance path GX? Thanks calibrated be factory any Hi, you sensor as

Shacey Petrovic

There very Dexcom. with we're working closely is a chance and

So incorporate terms do do as can the and our once-a-day program. they hands to GX what develop, technical that on focused and calibration product of on we GX, But so feasibility. right and technology now, in we'll get it development

Ryan Blicker

progress you with Got And anything on your about one you. existing update a one it. partners if public And you XXXX? Drug believe can say in more maybe in be do a Delivery. position to or Delivery your then Is Thank provide of will partners? Drug there not,

Shacey Petrovic

It's tough say. to

their feasibility are whether the under suited of and involved terms molecules tight determining very clinical longer-term these agreements for programs. There's in not pod, early and unfortunately, the confidentiality we think, I are molecules a if with are endpoints. partners, also pass technical lot our and or pharmaceutical in these clinical

tell work there's and contributor that, to terms a are it's update years, seven a growth I in while. be going takes that this on progress point, be don't everybody to revenue about excited – that's significant underway. diverse be I in just we eager an because enthusiasm driver, five a And as a we're if But at the today of taken certainly to tangible nonetheless, to so to it's all of is can't a that We're more don't way. I the I if making more going update to able a I of longer-term just it's to we XXXX. – business, and But this that really it want stream. in can't be do you going really diminishment fast think we forward think be

Operator

comes question Kyle next Rose Our Canaccord. with from

Kyle William Rose

Great. Thank hear Can you question. the me all taking very much for you right?

Patrick J. Sullivan

Gotcha.

Kyle William Rose

of market previous to partnerships call five about have QX year, dovetail Delivery just are question around there that topic. four somewhere wanted I off on we're the the believe talked about you on Drug on last while you somewhere the along the I is the lines we've first call, in this to partner the Lilly's potentially to maybe at come three point it's that some four the so years going market, so still Obviously, still to be got into still five hits years, – one XXXX? down, year fair? to that we're still

Shacey Petrovic

that true indicative. first or really not it's give all of it's and we of partner, helpful not it's being that numbers we think to the don't specific – they're just generally really pipeline. Lilly not trying The are why true I of that deals not is because the be reason transparent, That's

really You stage of opportunities have with product large whether more a feasibility have early need revenue-generating associated a become scale, a like near-term not endpoints we partner could that or in a Amgen, is agreements and could have a us. commercial and for terms they opportunity, actually which or them dozen risk more technical lot their

that want didn't updating we in as soon still a number still we that, public why that risk/reward the deals, can forward as insight, but everybody of deals we you of of they partnerships. versus stopped first larger to these in as all terms with and number to that's looking So progress of we're giving become of and the make be Lilly generally, the terms we of mislead get the

Kyle William Rose

quick you're appreciate Dash I out that one, there. extra any new the product But launch color mid-XXXX. got support And transition. questions, building then with you've two Great. internationally expectation, major coming a to a obviously, in infrastructure major

for start secondarily, the expect now, refresh we any U.S. talked we half about the then for launch? think timelines expectations the clinical for investments reps, so the just third IDE in when Just can first approval? exiting operations, (XX:XX) Horizon? can in the of you You feet on on And XXXX give and XXXX street about to get a us the

Shacey Petrovic

Sure.

force terms expected we're to when a always of that, footprint, the the out productivity evaluating expanded mean, first where sales be. sales increasing and about we approaching year so exactly I in we from when we're in we that's So – last

key the And exactly IDE, sure as going a I review we're Horizon come we that clinical adjust timing. are so always around we're in other insights excited you development February. performance. well, think any that, just give do, we're and with do data and its was evaluating out but this our of far, question successful about commercially to but for color then don't on Dash it's that in as resourced and I that with as think our development we'll we'll in appropriately, and the nicely, we accordingly. on we we're with expected. guidance We're But launch give XXXX, very certainly, the did of more prepared And in so, going comes that on progressing make investments and XXXX, And track to of Dash all we we programs, we'll

XXXX enhancements, XXXX, going at terms of I as years, guidance really capabilities you progress. bring really of end of mobile two experience with serious to keep this and and with guys would concentrated working updated Dash to insulin. we're the we user it's out, to giant couple make years I is we're out, of terms point, next in and we're the so we're point early change no So But market that. but – and mean, in hard meaningful over going just forward innovation really Dash a with leap excited really about the

going ever, the analytics people thing launch it systems get clinicians about the really we Horizon, the effectively, time is, and these to think about going which their mobile something and impact excited way Omnipod potentially program to before, to a And data able so physicians, I that's the to could it automated are the really and that their about access. is market first we're that For use as be lot data to relates delivery, users we're just learning think how market takes needs to they're population payers other hadn't how in for what that insulin efficiently, phone, we see going and train get a the how on to in happening, meantime. analytics, in get and are to

program. really So and our frankly we're hoed take there's is of into incorporate able right be to just another, being lot by to and them fortunate now, those that ground a lessons

Kyle William Rose

you much the questions. Thank for Great. taking very

Shacey Petrovic

Thanks.

Operator

from question comes Wedbush. Tao with next Levy Our

Tao L. Levy

Good Thanks. afternoon. Great. (XX:XX).

Shacey Petrovic

Hey, Tao.

Tao L. Levy

you first, generate with of or – events some in how on Maybe Hey. guys Europe. kind about already you've these Ypsomed, to are Was your you in hosted doing the just you're coordination own events talked that interest?

Shacey Petrovic

attendance fund them no, meaning, and coordinated, kind of doing most actually of all, in course, and events, guess, we were Well, I together. that we they of not I but those execute think knew if them didn't were of they

Tao L. Levy

the now possible marketing is you're the parties mean, that Okay, of on? internationally that that some seeing I events growth so is both are it result additional reporting of

Shacey Petrovic

so. I don't think

in all, of first – those happened think last month. the I of those most

they're... think don't I So,

Tao L. Levy

Okay.

Shacey Petrovic

week, were significant that they exception were events. (XX:XX) the happened ...driving with they last and – clinician-oriented clinician-oriented one of

Patrick J. Sullivan

right. Just getting chat, enough to

Shacey Petrovic

Yeah.

Patrick J. Sullivan

we're the face and European new us patients. So access those of into and think with events gives types clinicians I market, and time hosting

Tao L. Levy

so then I to sales the on any a there? Ypsomed, And will price Yeah. update chance they your Got you. lower on to there. And reimbursement do, France there's thought the you to to sell incentivized be reduce reimbursement that might front? product they'd continue just they that if

Shacey Petrovic

aggregate an is Ypsomed across the to continent. pricing Our

So don't would it... think I we lower

Tao L. Levy

Okay.

Shacey Petrovic

is – shape there's good if but we market, (XX:XX) there. as feel of ...because in reimbursement

So...

Tao L. Levy

Thank you. Okay.

Shacey Petrovic

You're welcome.

Operator

from Our Leerink Partners. with Danielle next comes question Antalffy

Danielle J. Antalffy

congrats Thanks the Hey, guys. good on quarter. and afternoon, much great another so taking for question,

Shacey Petrovic

Thanks, Danielle.

Danielle J. Antalffy

One Two Omnipod U.S. International. on problem. quick No one the questions. on business,

are outperforming base So installed expectations think in you our first in at business? seeing and on you least that U.S. I the grew expectations are What still the the U.S., Shacey, as you It sounds consensus like expected.

So is expected some mix it performance? getting higher is there driving ASPs, distributor what's changing, utilization, that's are on the than you higher of going the better

Shacey Petrovic

don't improvements rates across kind all using (XX:XX), continue think a of to incremental improve. more utilization time Net we practitioner users those given But in of there's I say pods I'd things. see so healthcare we or period. see utilization

I and specific a the improving on great couldn't we're estimate on access market growth installed although there. base moving great quality see attrition, to product the customer But and an resulting thinking and continue on and give some likely We progress just needle it's experience. you

too, so we've that's that all positive is that business. of had – driving So channel with favorability and some continued then mix,

Danielle J. Antalffy

then it. I correct International, went and there, direct Got me country wrong, direct to Canada? you do last if go you where manner, was And when And... think in guys helpful. That's shifting the similar a I'm

Shacey Petrovic

Yeah.

Danielle J. Antalffy

that, highlighted the is you growth driver. and wondering today, ...I'm strong

So and how you might over when could growth saw that Thanks Canada, so I'm whether wondering we you accelerate some a proxy color in you installed the if see base on what be Europe. give take could in for much.

Shacey Petrovic

we've change a growth really and us years terrific and starts We seen really Sure. a in terms just function the product over there, two now, from smooth strong has GSK I ago, new our that patient team, of new two step really success. years that been Yeah, Canada or for back market guess, transition little bought ago. And business. of distribution

So I of in Europe. we're and going a as a the kind can in and transition how great successfully we've we markets terms very we of this, view so we do much did got think indicator blueprint of there do this, how Canada would to

markets this I Nordics, not think said yet, are almost XX-plus the thing add there's other on then discrete. the in business. We've to Europe up maybe the the and call very it when percent XX% you really before, account business, but of markets major is, four for of you're the that

really several distributors, so we to just continuity straightforward, of patient Canada certainly business, successfully business by how a concentrated do that it's and was do but and principle and are of discrete need a those in that proof and we markets know can transfer, this, pretty it So third-party served we ensure care. to

Danielle J. Antalffy

All so right. Thanks much.

Shacey Petrovic

Thanks, Danielle.

Operator

Raymond James. with Bedford from Jayson next Our comes question

Jayson T. Bedford

progress. the congrats on and afternoon Good

just seems larger base. it the in international quarter-on-quarter XX% business was it So, growth, summer off quarter couple, and this of grew a more international a certainly in lift on always XQ, there's sequentially you was the but months, north the like Europe over a at pronounced, in

of new could Ypsomed reimbursement explain So, or quarter my is, the question any that there was that were there kind to sequential any was in added countries that jump? third here, sold new the

Shacey Petrovic

some then the added, our transitioned continent dynamics there Europe, were continued in that. that we new no countries drove entering Jayson, the the no in in anticipate and but market and I of some the into – business newer just like countries have changed strong until any we France, that countries nothing really No, strong terms after across growth mentioned, of of in countries growth new don't

Jayson T. Bedford

you Omnipod can did selling France? when remind And Okay. Ypsomed us in start

Michael L. Levitz

It was the middle of It last was... Mike. year. is This

Shacey Petrovic

July?

Michael L. Levitz

roughly. end the – Yeah. It the I was towards think QX of

Shacey Petrovic

Yeah.

Michael L. Levitz

really just it the materially half – happened the accelerate of to of in really through growth then beginning the this the the continued year. impacted year of part mean latter significant and I

Shacey Petrovic

Yeah.

Jayson T. Bedford

the down follow-up, the the quarter, in Delivery quarter-on-quarter. a implied Drug fourth year-over-year, just is guidance Okay. business And as

around a that XXXX? You there, of what in something just then segment Can to the explain growth you mentioned, is and orders. timing you would also, on return this went Mike, expect to

Michael L. Levitz

years, Well, work is we I we've new that on the our to there's timing between try work QX in terms the the even of in throughout couple think – it. to quarters, forecast We nothing it say piece last perfect fair of the we not business year of description Drug science, Amgen the with saw QX, said it's their of them – it's last and that QX. timing Delivery between works the has always consistent production for largest this out over with we a we between what The QX not expect all. changed shipments that there's guidance the at saw year with and year for that year, and

terms and spread a if takes, what over of it just you even quarter implies $XX is not it there's beginning the So but guidance a which pretty much gave saying even, by confirmed the at perfectly the it's just getting year, here, quarter, puts fourth in science the in for and million quarter. we we're line with perfect we've of

speak of really there's So there. to nothing

very what we'll looking very XXXX and year, we're forward have next XXXX, so say be February, guidance into we're we're that about excited relates to very, the but just that is in this giving to pleased for with As the going February. we it I momentum year, will

Operator

Thank you.

from question Northland next comes with Your Securities. Kalia Suraj

Suraj Kalia

Good quarter. afternoon, Congrats everyone. on an excellent

let with me Libre If you, would we range the is, data me Omnipod indicate, you ask reason for integrated issues of from of to And either has Libre? the prevent as Pat that Shacey, So, let Europe. the all – seems start most an out. for Libre hyperglycemic in I know within the creating and numbers

replacement I aware U.S. think, claim so well they pretty the have the are guys of in you

sense doesn't Just with curious it's makes if make if sense even that's radar possibility, configuration? what a on such or a the what screen

Shacey Petrovic

what of phone the to indicating all really ask on customers made and to all I It's the data. our using also mean. also the market viewing their data. GX of kind and using in most United everybody a example, wanted in States data, data are their going GX it's for does put to decision really and customers Europe go think their for phone and of We mobile people you where because our was and integration our that's that where, strategic in Europe, Libre using the have people mobile research of are where

users that that on experience, integrated can give data they using. Omnipod that so an data of rationale right put using sensor was they where that So, strategic our view their and our data they're generation the view phone, whatever of they're kind Omnipod sensor whatever

that we're users that's Europe also who our approach and that of Dash and having experience are to know think our there enable We And Omnipod been excited using user Libre a so, experience. are really starting I in plenty do for population. about great

that's that with happening good are And both today, so, people getting we products. user of really know a those experience

Suraj Kalia

should or be are on are issues about things not popping side. issues that in And on PDDA I (XX:XX) seeing CGM the and pump any your not saying there receivers in Shacey, on you the right the reimbursement that? criteria of mentioned of some kind Dash, terms side am in I DME-based Am the in up of those there right smartphone, the that saying

Shacey Petrovic

issue you're is primarily think until and do Medicare so have that that not DME I – tied that do not problem. we Pat have describing Medicare don't to reimbursements, secures we it, reimbursement, we

Patrick J. Sullivan

or more to. those either we Medicare it Omnipod Medicare nicely with deal and the we're either I reimbursement to with into Part Thanks the are D, from if need schemes the No, think happy for Part B CMS and Part one after we prepared but going were dig. D, fits of

Operator

you. Thank

Our last with Steven Oppenheimer. question Lichtman from comes

Steven Lichtman

guys. Thanks. Hi,

how has your investment run what get today and that comparison that to OpEx to to view salespeople $XX ground, next million few approximately o-U.S. years? Ypsomed $XX the to On on in the need in million feet go where you does the go to street on many rate direct, the does over

Michael L. Levitz

and This to is if Mike. anything she'd I'll obviously. speak like that, add can Shacey

about we're Europe. to this understand, important thing her Shacey comments, markets in one the in really and alluded to that in that's So

they're of they're all, second different concentrated, one from all, very and another. of First

and And one so France you're me France, in that as dealing in an a few in markets, example, so, other call really specifically. let out

home You're providers. with dealing health

or sell strategy patients, you'd you what be, in United to you're might with Canada so, very say to than than I the to where directly directly interact go-to-market should so allowed from And you a not see is what patients, or and in the different States might see go-to-market.

core are may distributors Europe, markets. people and need of a nature, we're multiple is different. those in in we markets other in And you number concentrated to smaller in because the we markets, few those much continue So to use have in

by it to we have that might country. in of upon terms vary really in people going the the So, of number needs is country, that based

Shacey Petrovic

Yeah.

as I continues on. best add would and continue so growth that commercial only grow what support is, that just best thing we into new have The as to will think as enter Mike we're support our continually customer markets, base. we we the right business right can the footprint, I we going to is States evaluate that in is United

Steven Lichtman

of some any of you've Thanks clarification. to Great. want from on? million I or XXXX, started separate $XX $XX just sorry, that. And million quick stand-up the Is here costs then, the that in one is for

Michael L. Levitz

So been $XX in we've to our as of be the them this much estimate but said, on costs. starting, nature. we've $XX currently of last said establishing Most most smaller about part as $XX The startup will are the we the they call, the to year will million. XXXX. But those numbers we having in in probably in be XXXX, recurring spending that first some we be million of the operations of Europe, are million, costs, half of they're are starting also and startup

Steven Lichtman

Thanks, Mike. Thanks, Shacey. it. Got

Operator

time. showing Sullivan. at the turn question would to Patrick any I to And this like I'm conference further not over back

Patrick J. Sullivan

creating raising employees I the for am the operational the like and you, you success. is operator. to thrilled our diseases. dedication an and Thank February. quarter-over-quarter call call actual for of speaking and improve today, on with absolutely in team proud at and The us thank and performance outstanding lives record burden the hard other to dedicated team to strong of this Thank diabetes In quality, work the very growth. long-term fourth forward closing, the living delivering of quarter you improving customer track earnings experience, ease people (XX:XX:XX) look organization on bar to also the with the the we their and for Insulet excellence, with quarter product joining I'd of

Operator

today's for a you. you and wonderful this Thank your Ladies conference. Thank and have gentlemen, concludes participation day.

may You all disconnect.

Insulet (PODD) 2 Nov 172017 Q3 Earnings call transcript